Diabetes continues to be one of the most significant global healthcare challenges, creating a growing demand for advanced insulin management solutions. As healthcare providers and patients increasingly seek more effective, convenient, and precise methods of insulin administration, the insulin delivery device market is experiencing remarkable growth.

According to recent market analysis, the global Insulin Delivery Device Market was valued at USD 32.6 billion in 2024 and reached USD 35.3 billion in 2025. The market is projected to grow at a CAGR of 8.3% from 2025 to 2030, ultimately reaching USD 52.7 billion by 2030.

Download the Complete Market Report

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092

Market Overview

Insulin delivery devices play a crucial role in diabetes management by helping patients administer insulin accurately and conveniently. The increasing prevalence of both Type 1 and Type 2 diabetes worldwide is a primary factor driving market expansion.

Several factors are contributing to market growth:

• Rising incidence of diabetes globally
• Growing prevalence of Type 1 diabetes
• Technological advancements in insulin delivery systems
• Increasing government support and reimbursement programs
• Expanding healthcare expenditure on diabetes care
• Growing adoption of smart and connected insulin devices

These trends are encouraging manufacturers to develop innovative products that improve treatment outcomes and patient quality of life.

Insulin Pumps Emerging as the Fastest-Growing Segment

Based on device type, the market is segmented into:

• Insulin Pens
• Insulin Pumps
• Insulin Pen Needles
• Insulin Syringes
• Other Insulin Delivery Devices

Among these categories, insulin pumps are expected to witness the highest growth rate during the forecast period.

Insulin pumps are compact, computerized devices designed to continuously deliver insulin throughout the day. They offer superior glucose management compared to traditional injection methods and are increasingly preferred by patients with Type 1 diabetes.

According to a 2023 report from the University of Alabama at Birmingham (I-JAB), approximately 350,000 individuals in the United States currently use insulin pumps. Their ability to improve glycemic control, reduce complications, and enhance patient convenience has significantly increased adoption rates among both adults and children.

The growing popularity of Continuous Subcutaneous Insulin Infusion (CSII) technology is expected to further accelerate market growth.

Type 1 Diabetes Segment Holds the Largest Market Share

Based on application, the insulin delivery devices market is divided into:

Type 1 Diabetes

Type 2 Diabetes

The Type 1 diabetes segment accounted for the largest market share in 2024.

According to the International Diabetes Federation (IDF) Atlas 2025:

• Approximately 9.15 million people globally were living with clinical Type 1 diabetes in 2024.
• Around 503,000 new cases were diagnosed during the year.
• Nearly 1.81 million patients were below the age of 20.
• About 6.28 million patients were aged between 20 and 59 years.
• More than 1 million patients were aged 60 years and above.

As diagnosis rates continue to rise across all age groups, demand for innovative, user-friendly, and technologically advanced insulin delivery solutions is expected to increase substantially.

North America Leads the Global Market

Geographically, the market is segmented into:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America held the largest share of the insulin delivery devices market in 2024.

Key growth drivers include:

High Diabetes Burden

According to the IDF Atlas 2025:

• The United States has approximately 38.5 million adults living with diabetes.
• Canada has approximately 2.8 million adults living with diabetes.

Rising Healthcare Expenditure

Diabetes-related healthcare spending reached:

• USD 327.5 billion in the United States
• USD 13.7 billion in Canada

Government Support and Innovation

Government agencies such as the FDA continue to support the development and approval of innovative diabetes management technologies, including precision medicine-based insulin delivery systems and connected diabetes care solutions.

Competitive Landscape

The insulin delivery devices market features several established global players focused on product innovation, strategic collaborations, and geographic expansion.

Key market participants include:

• Embecta Corp. (US)
• Novo Nordisk A/S (Denmark)
• Ypsomed (Switzerland)
• Medtronic plc (Ireland)
• Tandem Diabetes Care, Inc. (US)
• Sanofi (France)
• Eli Lilly and Company (US)

Company Spotlight: Embecta Corp.

Embecta Corp. became an independent company following its spin-off from Becton, Dickinson and Company (BD) in April 2022.

The company offers:

• Insulin syringes
• Insulin pen needles
• Diabetes management solutions

Embecta operates in more than 100 countries and manufactures approximately:

• 6 billion pen needles annually
• 1.5 billion syringes annually

In May 2023, the company announced a partnership with Tidepool to develop an Automated Insulin Delivery (AID) system specifically designed for individuals with Type 2 diabetes.

These initiatives strengthen Embecta’s position as a leading innovator in the insulin delivery devices market.

Company Spotlight: Novo Nordisk A/S

Novo Nordisk remains one of the most influential players in global diabetes care.

The company offers:

• Insulin therapies
• GLP-1 analogs
• Obesity treatments
• Intelligent insulin pens
• Dose Check insulin dose guidance software

Novo Nordisk has a significant global footprint, with operations across more than 170 countries and research, manufacturing, and commercial facilities worldwide.

The company continues to expand its connected drug delivery capabilities. In June 2023, Novo Nordisk acquired BIOCORP Production SA, strengthening its smart insulin pen portfolio and advancing digital diabetes management solutions.

Products such as NovoPen 6 demonstrate the company’s commitment to integrating digital health technologies into insulin therapy.

Future Outlook

The future of the insulin delivery device market is being shaped by digital health integration, smart insulin delivery systems, connected care platforms, and patient-centric innovation.

As diabetes prevalence continues to rise globally, healthcare providers and manufacturers are increasingly focusing on technologies that improve treatment adherence, enhance glycemic control, and reduce long-term complications.

With strong support from healthcare systems, favorable reimbursement frameworks, and ongoing technological advancements, the insulin delivery device market is expected to maintain robust growth through 2030.

Request Sample Pages

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=107632092

Conclusion

The insulin delivery device market is entering a transformative phase driven by increasing diabetes prevalence, technological innovation, and growing healthcare investments. From advanced insulin pumps to intelligent connected pens, next-generation delivery solutions are improving patient outcomes and redefining diabetes management worldwide. As adoption continues to accelerate, the market is well-positioned to achieve its projected valuation of USD 52.7 billion by 2030.